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Background
Sickle cell crises are commonly treated at our institution given 
its large sickle cell patient population and well-established 
hematology department. While pain management is a crucial 
aspect to these patients’ care, it is important to remember that 
a vaso-occlusive crisis can be life threatening. Many organs 
can be at risk, including the lungs (acute chest syndrome), 
brain (stroke), eyes (retinopathy) and as in our case, the liver. 
We hope this case report can become incorporated in future 
differential diagnoses pertaining to sickle cell crises.
Case Presentation
A 48-year-old black female with a past medical history of 
sickle cell anemia, HIV on antiretroviral therapy, pulmonary 
hypertension on 4L of home oxygen, lymphocytic interstitial 
pneumonitis, chronic obstructive pulmonary disease, remote 
history of deep vein thrombosis, and pulmonary embolism, 
presented to the emergency department with complaints of 
shortness of breath, increased abdominal girth and lower 
extremity swelling for four days. She also complained of 
lower back and leg pain typical of her sickle cell crises. Her 
prescribed medications included tenofovir/emtricitabine, 
atazanavir, ritonavir, folic acid, oxycodone/acetaminophen, 
oral hydromorphone, and furosemide. Her social history was 
significant for smoking one fourth of a pack of cigarettes daily. 
Investigations
On presentation her vitals were temperature 98.1°F, blood 
pressure 106/48 mmHg, heart rate 87 beats per minute, and 
respiratory rate 19, with an oxygen saturation of 88% on 4L of 
oxygen by nasal cannula. Her physical exam revealed scleral 
icterus, diffuse abdominal pain most pronounced in the right 
upper quadrant to palpation, hepatomegaly and abdominal 
distention. She did not have any lower extremity edema. Her 
initial labs showed a total bilirubin of 49.4 (mg/dl), direct 
bilirubin 42 (mg/dl), AST 165 (IU/L), ALT 110 (IU/L), alkaline 
phosphatase 434 (IU/L), ammonia level 150 (mcmol/L). Her 
coagulation studies were partial thromboplastin time (PTT) 
32, and an international normalized ratio (INR) of 1.9. She 
was also found to have a hemoglobin of 6.6 g/dL (down from 
9 g/dL three days prior to presentation), white blood cell count 
of 13.6 (B/L) and platelet count of 276 (B/L). Additionally, 
the Hemoglobin S (HgS) percentage was 90%. Her creatinine 
was 2.8 (mg/dL), urea nitrogen 74 (mg/dL), potassium 6.2 
(mmol/L), bicarbonate 6 (mmol/L), anion gap of 25. Her 
other serum electrolytes were within normal limits. Her lactate 
dehydrogenase was 1405 (IU/L) and haptoglobin <10 (mg/
dL). Her ABG showed a pH of 7.2, pCO2 24 (mm Hg), pO2 91 
(mm Hg). Lactate was 8.4 (mmol/L). Her CD4 count was 432. 
A limited abdominal ultrasound showed cholelithiasis with gall 
bladder sludge, but normal wall thickness and no pericholecystic 
fluid. The liver measured 22.1 cm in sagittal length consistent 
with hepatomegaly, but showed normal echogenicity and 
texture. There was no intra or extrahepatic bile duct dilatation. 
Renal ultrasound showed no hydronephrosis. An echocar-
diogram showed a pulmonary artery systolic pressure of 90 
mm Hg, normal left ventricle systolic function, right ventricle 
enlargement and decreased function, but no significant changes 
from a prior echocardiogram.
Differential Diagnosis
Table 1 highlights our initial broad, problem-based, differential 
diagnosis. In terms of the workup of her liver failure, the 
differential was narrowed by the aforementioned lab findings 
and imaging. The abdominal ultrasound did not show signs of 
biliary obstruction or thrombus. Hepatitis panels and initial 
screening for medication induced liver failure were negative. 
Given her initial liver function elevations and lactic acidosis, 
it was thought that a vaso-occlusive hepatic crisis was most 
likely the etiology of her liver failure. Tenofovir, known to 
cause a severe lactic acidosis, was initially held. The patient was 
empirically started on broad-spectrum antibiotics, but with 
negative bacterial cultures and lactic acid resolution following 
appropriate intervention, the vaso-occlusion from sickled red 
blood cells (RBC) leading to end organ ischemia was believed 
to be the most likely etiology. Likewise, this would also explain 
the pathogenesis behind her renal failure.
The patient was admitted to the medical intensive care unit. 
A femoral pheresis catheter was urgently placed and she 
received six units of red blood cell exchange transfusion. Her 
Hemoglobin S percentage decreased to 42% from 90% after the 
transfusion and her hemoglobin increased to 9.4 (g/dL), while 
total bilirubin decreased to 36.3 (mg/dl) and direct bilirubin 
29.4 (mg/dl). 
Outcome and Follow-up
Once stabilized, the patient was transferred to the general 
medicine floor for routine care. Her hospital course included 
episodic shortness of breath and hypoxia, which improved with 
diuresis. Five days after presentation, her total bilirubin reached 
a nadir of 9.4 (mg/dl), with a direct bilirubin of 6 (mg/dl) and 
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AST / ALT levels of 76 (IU/L) and 140 (IU/L) respectively. Her 
creatinine stabilized at 1.6 (mg/dL) from a peak of 3.2 (mg/dL) 
at time of discharge. 
Discussion
Sickle cell disease (SCD), as a hemoglobinopathy, can cause 
widespread sickling and vaso-occlusive events in all organ 
systems. Although not as commonly seen, liver involvement 
can be life threatening. Sickle cell hepatopathy has been a 
term used to generally describe varying etiologies of liver 
dysfunction in sickle cell patients. Multiple blood transfusions 
subject patients to increased risk of infectious processes, such 
as hepatitis B and C, and iron overload. Chronic hemolysis also 
causes sickle cell patients to be more prone to development of 
pigmented gallstones, which can lead to acute cholecystitis and/
or biliary duct obstruction. Hepatic sequestrations can cause 
hepatic enlargement and rapidly falling hemoglobin. These 
complications can present similarly to acute sickle hepatic crisis 
and need to be excluded to make a diagnosis.1-4
Acute sickle hepatic crisis has been seen in about 10% of patients 
with SCD. Common presenting symptoms include right upper 
quadrant pain, low-grade fever, tender hepatomegaly, jaundice 
and elevated liver function tests. The pathogenesis stems 
from sickle cell thrombi in the sinusoidal space leading to 
ischemia. In a more extreme form, this can lead to intrahepatic 
cholestasis, which is rooted in widespread ischemia secondary 
to a massive sickled RBC load leading to hepatocyte edema 
and obstructive biliary outflow.2 AST/ALT levels can run in the 
thousands, with total bilirubin levels reported as high as 300.5 
Coagulopathy is common and worsens as hepatocyte necrosis 
spreads. Histological hallmarks include sickle cell thrombi 
within sinusoids that can lead to bile plugs formation in 
canuliculi, inflammatory cell infiltration and hepatocyte edema/
necrosis from prolonged ischemia. Such hepatic damage makes 
the prognosis of sickle cell intrahepatic cholestasis poor. Of 
the limited published cases report, mortality from intrahepatic 
cholestasis is greater than 50%.5
The cornerstone treatment for intrahepatic cholestasis is 
rapid HgS fraction reduction. While there are no specific 
studies looking at target fractions in acute hepatic sickle cell 
crises, previous studies focusing on stroke risk in sickle cell 
patients show risk reduction with HgS fractions less than 30%.6 
Reduction can be achieved through exchange transfusion 
using pheresis, which allows for better fluid management and 
avoids rapid changes in volume that can impact intravascular 
viscosity. Additional supportive treatment includes hydration, 
pain management, coagulopathy correction, and electrolyte 
monitoring.
Liver transplantation has been proposed as a therapeutic option 
in patients with fulminate failure from an acute crisis.7 However, 
transplantation experience is very limited. Only 18 transplant 
cases have been reported in the literature.7 Hepatic vascular 
re-thrombosis and associated phenomenon (i.e. neurovascular 
injury) from post-operative sickle cell crises add to the inherent 
morbidity/mortality risk.7 Consequently, the overall mortality 
rate in SCD patients with acute hepatic failure undergoing 
transplant is 60%.6 Optimization of post-operative management 
will improve as transplantation is considered early in patients 
where fatal hepatic failure is anticipated.
Given the clinical presentation of our patient, she showed signs 
of ischemia with an elevated lactate, liver and kidney failure. 
Her hepatitis panels were negative, and ultrasound showed 
no signs of obstructive disease. Given her significant direct 
hyperbilirubinemia, it was thought that she was suffering from 
acute intrahepatic cholestasis causing liver and renal failure. 
This was confirmed by her immediate improvement after red 
blood cell exchange transfusion. This case reiterates the need 
for early detection of liver involvement in sickle cell disease. 
Early management with exchange transfusion usually prevents 
potentially fatal liver failure.1
Key Points
•  Acute sickle cell hepatic crisis is an uncommon, but potentially 
fatal sequela of sickle cell disease if not diagnosed early in the 
disease course.
•  Common findings include profound jaundice, hepatomegaly, 
high AST / ALT, total bilirubin and renal failure.
•  Primary therapy is aimed at rapid reduction of the HgbS 
fraction through exchange transfusion via pheresis.
•  Liver transplantation is a possible option in patients with 
fulminant hepatic failure.
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